Facebook
X
LinkedIn
ForwardUnique Challenges with Clinical Trials for Radiopharmaceutical Therapy
While most oncologists are familiar with the development, execution and reporting of interventional clinical trials that improve patient outcomes, there are unique challenges that must be considered when evaluating radioactive drugs. These encompass institutional, radiation safety, budgetary, cooperative group, and regulatory concerns. Three unique perspectives from experts in drug development, regulatory affairs, and clinical investigation are presented.
Target Audience
This meeting was designed to meet the interests of medical oncologists, radiation oncologists, physicists, nurses, diagnostic radiologists, radiation therapists, radiation dosimetrists, specialists, nuclear physicians and practice administrators.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Understand unique challenges that RPT trials pose for investigators, institutions, and patients.
- Understand regulatory hurdles for the clinical investigation of RPT.
- Highlight opportunities for development and implementation of novel therapies with radioactive drugs.
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 0.75 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 0.75 Certificate of AttendanceThis activity was designated for 0.75 AMA PRA Category 1 Credit™.